Obesity
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global obesity drug development, market trends, and regulatory landscapes. Drive your pharma strategy with NovaPharmaNews intelligence.
Showing 1–9 of 9 articles
Quick answer
NovaPharmaNews Obesity hub for EMA covers 9 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Novo wins UK approval as race to launch weight-loss pill intensifies
EMA's CHMP Recommends Oral Wegovy Approval, Expanding Obesity Treatment Options in Europe
CVS Restores Coverage for Eli Lilly's Obesity Medications
Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 2 Obesity Trial, Outperforming Current Market Leaders
Novo Nordisk Presents New Wegovy Data for Women with Obesity at European Congress on Obesity 2026
BioPharma Clinical Trials: Gene Therapy, Obesity, and Oncology Updates
Pharma 2026: Key Takeaways from EU Biopharma & Medtech
Reuters Pharma EU: Funding & Dealmaking Key Takeaways
FDA Approves Idvynso, Ascentage Pharma at ASCO 2026
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.